Xvivo Perfusion AB (publ) (LON:0RKL)
London flag London · Delayed Price · Currency is GBP · Price in SEK
459.50
-3.84 (-0.83%)
At close: Feb 21, 2025

Xvivo Perfusion AB Revenue

In the year 2024, Xvivo Perfusion AB had annual revenue of 822.42M SEK with 37.63% growth. Xvivo Perfusion AB had revenue of 227.56M in the quarter ending December 31, 2024, with 46.12% growth.

Revenue
822.42M SEK
Revenue Growth
+37.63%
P/S Ratio
n/a
Revenue / Employee
4.84M SEK
Employees
170
Market Cap
1.07B GBP

Revenue Chart

* This company reports financials in SEK.

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024822.42M224.87M37.63%
Dec 31, 2023597.54M182.25M43.88%
Dec 31, 2022415.29M156.91M60.73%
Dec 31, 2021258.39M78.53M43.66%
Dec 31, 2020179.86M-40.98M-18.55%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AstraZeneca 43.19B
GSK plc 31.38B
Haleon 11.24B
Smith & Nephew 4.46B
Hikma Pharmaceuticals 2.39B
ConvaTec Group 1.74B
HUTCHMED (China) 483.31M
Oxford Nanopore Technologies 167.75M
Revenue Rankings